A Phase I Single Dose Escalation Study of Two Dosing Schedules of BI 6727 Administered Intravenously in Asian Patients With Various Solid Cancers With Repeated Administration in Patients With Clinical Benefit.

Trial Profile

A Phase I Single Dose Escalation Study of Two Dosing Schedules of BI 6727 Administered Intravenously in Asian Patients With Various Solid Cancers With Repeated Administration in Patients With Clinical Benefit.

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Apr 2014

At a glance

  • Drugs Volasertib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 20 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Jul 2011 Planned end date changed from 1 Jul 2011 to 1 Sep 2011 as reported by ClinicalTrials.gov.
    • 27 Jul 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top